Compare iShares MSCI Taiwan ETF (EWT) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Nuvalent Inc — how do they compare? iShares MSCI Taiwan ETF trades at $99.98, while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is trading nearer its 52-week high, iShares MSCI Taiwan ETF nearer its low. Which is the better fit depends on your goals.
| EWT | NUVL | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $111.53 | $123.96 |
52-Week Low | $58.05 | $72.16 |
Market Cap | — | $9.81B |
Enterprise Value | — | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $100.60, down 1.26% on the day amid neutral technical signals. The ETF has delivered exceptional performance with a 100%+ gain in 2026, driven by Taiwan's dominant semiconductor sector and AI infrastructure exposure. Current technical indicators show mixed signals with bullish moving averages but neutral oscillators, while support levels cluster around $99-$101.
The outlook remains favorable given Taiwan's critical role in global semiconductor supply chains and AI infrastructure growth, though stretched valuations and geopolitical tensions with China present significant risks. Institutional interest remains strong due to concentrated exposure to TSMC and other tech leaders, but investors should monitor dollar movements and regional stability.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, amid a pending $124 per share acquisition by GSK. The stock shows a bullish technical signal with moving averages supporting upside, though RSI levels suggest overbought conditions. Fundamentally, the company remains unprofitable with negative ROE and ROA, while cash flow is sustained by financing activities. Recent news is dominated by merger investigations and strategic rationale for the GSK deal.
The investment outlook hinges on the acquisition closing at $124, offering limited upside from current levels. Risks include shareholder litigation and regulatory scrutiny, but the deal provides a clear exit amid ongoing losses. Analyst sentiment is mixed with a slight hold bias, reflecting uncertainty around deal completion and fairness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
